High levels of the amyloid-beta (Aβ) peptide have been shown to disrupt neuronal function and 14 induce hyperexcitability, but it is unclear what effects Aβ-associated hyperexcitability may have 15 on tauopathy pathogenesis or propagation in vivo. Using a novel transgenic mouse line to 16 model the impact of hAPP/Aβ accumulation on tauopathy in the entorhinal cortex-hippocampal 17
Introduction 27
The accumulation of hyperphosphorylated, misfolded tau proteins into neurofibrillary tangles 28 (NFT), coupled with deposition of amyloid beta (Aβ) into extracellular plaques, are two hallmark 29 pathological features of Alzheimer's disease (AD) in the brain. The severity of cortical NFT 30 accumulation is strongly correlated with Aβ plaque load (1, 2) and is the principal 31 neuropathological variable associated with cognitive impairment in AD (1-4). The entorhinal 32 cortex (EC; Brodmann Areas 28 and 34) is a structure in the parahippocampal gyrus that plays 33 a critical role in spatial representation and navigation (5-7), and it is one of the first structures to 34 exhibit AD-related tauopathy and subsequent neuronal loss (8, 9) . As AD progresses, 35
considerable accumulation of pathological tau continues downstream into the hippocampus 36 (HIPP), which is extensively connected to the EC. Preclinical investigation into the stereotypical 37 spread of pathological tau along neuronal circuits in AD is an active area of research interest 38
(10-13). However, the biological mechanisms underlying the propagation of tau pathology in the 39 brain are currently unresolved. 40
In vitro studies utilizing rodent primary neurons have provided several mechanistic 41 insights into the pathophysiological relationship between cleaved amyloid precursor protein 42
(APP) fragments and tau. At the cellular level, accumulating evidence implicates Aβ oligomers 43
as a causative agent in the increased phosphorylation of tau at AD relevant epitopes (14) and 44 the missorting of tau and neurofilaments within the cell (15) . In mouse models of tauopathy, 45 stereotaxic injection of Aβ oligomers and fibrils into the brain results in significantly elevated 46 phosphorylation of tau (16) and the increased induction of neurofibrillary tangles (NFT) (17). 47
Thus, tauopathy in the brain may be aggravated by the increased production or accumulation of 48 APP fragments in vivo through direct interaction. For reviews of experimental models that 49
examine Aβ-induced tau alterations and pathology, see (18, 19) . 50
Alternatively, human APP/Aβ accumulation in the brain may trigger the aggregation and 51 acceleration of tau pathology via an intermediate, non-pathogenic mechanism. Indeed, several 52
reports now describe an effect of Aβ accumulation on neuronal network hyperactivity in Aβ 53
generating mouse models (20) (21) (22) ; for review, see (23, 24) , as well as in humans with mild 54 cognitive impairment (25, 26) . Spontaneous, non-convulsive epileptiform-like activity has been 55 described in cortical and hippocampal networks of relatively young transgenic mutant hAPP-56 expressing mice (21). In addition, increased proportions of neurons surrounding amyloid 57 plaques exhibit aberrant hyperactivity (20) and are accompanied by the breakdown of slow-58
wave oscillations (27) . Interestingly, neuronal hyperactivity has been shown to precede amyloid 59 plaque formation in the hippocampus, suggesting that the abnormal accumulation of soluble Aβ 60 drives aberrant neuronal network activity (28, 29) . Thus, it is plausible that Aβ-associated 61 hyperactivity can facilitate the progression of pathological tau in the brain, and does so indirectly 62 without the need for direct Aβ-tau interaction. Interestingly, stimulating neuronal activity can 63 facilitate both Aβ and tau release from neurons in vivo (30, 31) , and exacerbates Aβ deposition 64
and tauopathy in synaptically connected neurons (13, (32) (33) (34) . Mature tau pathology may in turn 65
aggravate Aβ-associated neuronal network dysfunction by further altering neuronal firing rates 66
and network oscillations (35), recruiting neuronal populations into a harmful feedback loop 67
involving protein aggregation and aberrant signaling. 68
In these studies, we utilize a newly developed AD mouse line to resolve the individual 69 effects of Aβ and tau pathology on neuronal activity in the EC. Mice that generate Aβ and tau 70
pathology were compared to littermates that generate either Aβ or tau alone, while non-71 transgenic littermates served as controls. We first demonstrate that hAPP/Aβ expression 72 aggravates tau accumulation in the EC and accelerates pathological tau spread into the HIPP, 73
supporting previous findings (36) (37) (38) . In vivo electrophysiological recordings in our mice 74 revealed distinct neuronal hyperactivity and network dysfunction associated with EC hAPP/Aβ 75 expression, but not tau expression. We then employed a chemogenetic approach in the 76 transgenic mice to combat EC neuronal hyperactivity, with the goal of reducing the 77 accumulation of pathological Aβ and tau along the entorhinal cortex -hippocampal (EC-HIPP) 78
network. Chronic attenuation of EC neuronal activity dramatically reduced hAPP/Aβ 79 accumulation in downstream hippocampus and reduced abnormally conformed and hyper-80 phosphorylated tau aggregates along the EC-HIPP network. Our data support the emerging 81
view that Aβ-associated hyperactivity plays a role in AD pathogenesis, specifically by acting as 82
an accelerant of tau spread along synaptically connected neuronal circuits in the brain. 83
Interneuron dysfunction has previously been described in hAPP expressing mice, 149
suggesting that shifts in the excitation-inhibition ratio within cortical and hippocampal networks 150 may be responsible for emergent epileptiform activity (21, 40) . We first plotted the average firing 151 rates of all EC single-units as a function of the waveform's averaged spike-width (µs). This 152 revealed a distinct population of hyperactive neurons in Aβ-generating mice that were 153 distributed along narrow and wide spike widths ( Figure 2D, purple) . We also noticed what 154 appeared to be a bimodal distribution in the scatterplot. To examine cell-type specific firing 155 patterns in our single-unit recordings, we then plotted cell frequency as a function of average 156 spike width ( Figure 2E ) (39, 41) . This resulted in a clear bimodal distribution of the cell 157 population, wherein narrow-spiking (NS) cells could be separated from wide-spiking (WS) cells 158
( Figure 2D-G) . Previous studies indicate that NS cells and WS cells likely correspond to putative 159
interneurons and putative excitatory cells, respectively (41). A total of 408 NS cells and 852 WS 160 cells were identified from our EC recordings across 20 mice (NS, 32.38% vs WS, 67.62% of 161 total neurons) (for detailed per animal cell-type information, see Table 1 and Methods). hAPP 162 (6.694 ± 0.778 Hz) NS cells exhibited increased firing rates compared to Control (3.757 ± 0.358 163
Hz) NS cells, while EC-Tau/hAPP (4.456 ± 0.688 Hz) NS cells and EC-Tau (3.760 ± 0.367 Hz) 164 NS cells did not ( Figure 2F ). Interestingly, hAPP (4.954 ± 0.275 Hz) WS cells and EC-Tau/hAPP 165 (6.174 ± 0.388 Hz) WS cells exhibited significantly increased average firing rates compared to 166
Control (2.693 ± 0.218 Hz) WS cells ( Figure 2G ). The average firing rate of EC-Tau (2.693 ± 167 0.180 Hz) WS cells did not differ from Controls. Applying a speed filter to the datasets revealed 168 similar effects on EC firing rates (Supplemental Figure 1B-C) . These data agree with previous 169
reports describing Aβ-associated dysfunction in hippocampal interneurons, and expand this 170 hyperactivity phenotype to both putative interneurons and putative excitatory neurons in EC. 171 Impaired neuronal network activity has been described in human AD (42) and in mouse 172 models of AD pathology (43) (44) (45) . To investigate the effects of hAPP/Aβ and tau pathology on 173 EC network activity in vivo, we examined the LFPs and compared oscillatory activity across 174 genotypes ( Figure 3 ). Initial, visual inspection of the filtered LFP signal in theta (4-12 Hz), low 175
gamma , and high gamma (65-120 Hz) frequency ranges, as well as the filtered LFP 176 spectrograms, demonstrate impaired theta rhythmicity in 16-month EC-Tau/hAPP mice 177 compared to non-transgenic Control mice ( Figure 3A-B analyzed the data to remove activity during bouts of immobility (Supplemental Figure 1D -F).
186
Similarly, we found an Aβ-associated decrease in % theta power, though this was accompanied 187
by an Aβ-associated increase in % low gamma power. Averaged, speed filtered % high gamma 188 power values were not significantly different across genotypes. 189
Overexpression of hAPP Swedish/Indiana has previously been associated with increased 190 locomotor activity in the hAPP/J20 mouse line (22, 48, 49) . To investigate locomotor activity in 191
16-month EC-Tau/hAPP mice, we analyzed the position data from our recorded mice as they 192
performed a foraging task in the open field arena ( Figure 4 ). We did not detect significant 193
differences between groups in the total distance traveled in the arena (m), % of arena coverage 194 or average speed (cm/sec) during exploration ( Figure 4A -D). To examine whether group 195 differences in locomotor activity exist within the initial phases of recording, we split the sessions 196
and examined performance measures in the first 5, 10 and 15 min ( Figure 4E-G (1mg -1 /kg -1 /day -1 ) into the peritoneum. EC spiking activity was noticeably decreased during the 229 last three weeks of CNO treatment (n=9 mice, EC-Tau/hAPP and EC-Tau mice) ( Figure 5A ), 230
and theta power was significantly reduced at the fifth (T5) and sixth week (T6) of CNO treatment 231 compared to baseline ( Figure 5B ), confirming chronic hM4D i DREADDs activation in vivo. After 232 6-weeks of hM4D i EC DREADDs activation, all experimental mice were sacrificed and 233
immunostaining was performed on horizontal brain sections to confirm EC DREADDs 234 expression and electrode placement, and to identify pathological Aβ and/or tau deposition along 235
the EC-HIPP network. An overlay of mCherry signal (hM4D i DREADDs) and eGFP (control in the right hemisphere was primarily localized to cell bodies and neuropil throughout the EC 239
and pre-and para-subiculum, with occasional mCherry signal present in the subiculum, and at 240
terminal ends of axons in the middle-and outer-molecular layers of the DG ( Figure 5C -D).
241
Importantly, we did not detect DREADDs mCherry crossover into the contralateral left 242
hemisphere. 243 EC-Tau/hAPP mice and hAPP mice that were administered 1mg -1 /kg -1 /day -1 CNO for 6-244
weeks exhibited a dramatic reduction in Aβ accumulation within subregions of the hippocampus 245 downstream of the DREADDs-activated right EC ( Figure 5E -G immunostaining along the EC-HIPP network, including progression into the dentate gyrus (DG) 275
and CA1 of the hippocampus ( Figure 6 ). MC1+ immunostaining revealed selective decreases in 276 abnormally conformed tau along the EC-HIPP network in our mice ( Figure 6 ). Representative 277
images from EC-Tau mice ( Figure 6A -E) and EC-Tau/hAPP mice ( Figure 6F -J) exhibiting Early 278
Tau pathology showed decreased MC1+ immunoreactivity within neuropil and cell bodies of the 279
DREADDs activated rPaS and rEC. These decreases were clearly evident in EC-Tau/hAPP 280 mice ( Figure 6G -H), as they possessed a greater number of somatic MC1+ immunostaining in 281
PaS and EC than EC-Tau mice ( Figure 6B -C). Notably, MC1+ immunoreactivity was not 282 decreased in the most lateral portion of the rLEC bordering the perirhinal cortex ( Figure 6H ), an 283 area lacking DREADDs-expression ( Figure 6G immunostaining could be seen in ipsilateral, downstream DG granule cells, CA1 pyramidal cells 290
and Subiculum in hM4D i EC DREADDs activated EC-Tau mice ( Figure 6N -O). Selective 291 decreases in MC1+ immunostaining could also be seen along the EC-HIPP network in EC-292
Tau/hAPP mice with Advanced Tau pathology, with notable reductions in somatic MC1+ 293
immunostaining in rPaS and rEC ( Figure 6Q -R) in the DREADDs activated right hemisphere, as 294 well as in rCA1 pyramidal cells ( Figure 6T ). 295
We then processed adjacent tissue sections from experimental mice to identify 296 phosphorylated tau using the phosphotau-specific antibody AT8 (Ser 202 /Thr 205 ) (53). Reductions 297 in somatodendritic phosphotau accumulation was also identified along the EC-HIPP network of 298 our hM4D i EC DREADDs activated EC-Tau/hAPP mice and EC-Tau mice (Figure 7 ). EC-Tau 299 mice exhibiting Early Tau pathology ( Figure 7A ) showed reduced AT8+ immunoreactivity in the 300 rPaS ( Figure 7B ) and rEC ( Figure 7C ) compared to analogous regions in the contralateral 301
hemisphere. EC-Tau/hAPP mice exhibiting Early Tau pathology showed a similar reduction in 302 AT8+ immunostaining ( Figure 7F -H). As significant tau pathology had not progressed into the 303 HIPP of these mice at 16-months, no hemisphere differences in HIPP subfield AT8+ 304 immunoreactivity were detected ( Figure 7D -E, I-J). EC-Tau mice ( Figure 7K ) and EC-Tau/hAPP 305 mice ( Figure 7P ) exhibiting Advanced Tau pathology showed reductions in AT8+ cell bodies 306
and neurites within the rPaS, rEC and rHIPP subfields. Somatic AT8+ immunostaining was 307 reduced in the rSub, rDG granule cells and rCA1 pyramidal cells of EC-Tau mice ( Figure 7M -O).
308
EC-Tau/hAPP mice showed reduced AT8+ immunostaining in rPaS and rEC of the DREADDs 309 activated right hemisphere, in addition to downstream CA1 pyramidal cells ( Figure 7T ). We also 310 stained adjacent tissue sections from experimental mice with the antibody CP27 (human Tau 130-311 150 ) to detect the distribution of total human tau along the EC-HIPP network. Similar to MC1+ 312 and AT8+ immunostaining, CP27+ immunostaining revealed selective decreases in total human 313 tau along the EC-HIPP network in the DREADDs activated right hemisphere of our mice 314 (Supplemental Figure 5 ). 315
The extent to which chronic hM4D i EC DREADDs activation reduced pathological tau 316 immunoreactivity in the hippocampus varied across mice, with some mice showing strong 317 effects in some regions and others subtle effects. In addition, reduced tau pathology in certain 318 mice was readily detected using some, but not all, tau antibodies. This effect is illustrated in a 319
16-month DREADDs-activated EC-Tau/hAPP mouse, where reduced tau aggregation is 320 apparent in CP27+ immunostaining, but not in MC1+ or AT8+ immunostaining ( Figure 8A ). To 321 examine the downstream impact of attenuated EC neuronal activity on hippocampal tau 322 pathology, we performed threshold analysis for each pathological tau marker in the DG, CA1 323
and SUB. We then calculated the % area of MC1+, AT8+ and CP27+ above threshold for each 324
ROI, similar to methods described in Figure 5G -H analysis. Finally, we generated a right 325
hemisphere versus left hemisphere ratio for each immunostained section and pooled them 326 according to hippocampal subfield ( Figure 8B ) and pathological tau marker ( Figure 8C ). Values 327 less than 1 indicate reduced tau accumulation in the treated right hemisphere, while values 328 greater than 1 indicate increased tau accumulation in the right hemisphere. Plotting the right 329 versus left hemisphere ratios by region revealed an effect of hM4D i EC DREADDs activation on 330 tau pathology in the DG (0.8029 ± 0.067) and CA1 (0.7598 ± 0.104), but not the Sub (1.0000 ± 331 0.117). Plotting the right versus left hemisphere ratios by tau marker revealed the strongest 332 effect of hM4D i EC DREADDs activation on CP27+ immunostaining (0.7714 ± 0.915). AT8+ 333
immunostaining was trending (0.7963 ± 0.097), while MC1+ immunostaining did not show an 334 effect (0.9951 ± 0.108). 335
In conclusion, our experimental data strongly support the emerging hypothesis that 336 hAPP/Aβ accumulation in the brain is associated with aberrant neuronal activity and network 337 impairment. Our data describe a role for Aβ-associated neuronal hyperactivity in accelerating 338 tau pathology along a well-characterized neuronal network that is vulnerable to AD pathology 339 and neurodegeneration. We further show that hyperactivity in this network can be targeted via 340
chronic chemogenetic activation to arrest the accumulation of both hAPP/Aβ and pathological 341 tau along the EC-HIPP network in vivo. 342
Discussion 343
The progressive, stereotypical spread of pathological tau along neuronal circuits in AD is an 344 active area of intense investigation. However, the underlying mechanisms that potentiate 345 pathological tau spread in AD are currently unresolved. We, and others, have proposed that 346 increased neuronal activity can exacerbate tauopathy either by promoting tau release from 347 neurons or by facilitating its uptake in synaptically connected neurons (32, 37) . To model the 348 functional interactions between hAPP/Aβ and hTau in a well-characterized neuronal circuit in 349 vivo, we crossed the Aβ-generating hAPP/J20 (Swedish/Indiana) mouse line (21, 54) with the EC-Tau 350 mouse line, wherein mutant hTau (P301L) is predominantly expressed in the EC (10, 11). Network 351 dysfunction and impaired cognitive performance have previously been described in relatively 352 young hAPP mice (21, 22, 48) . Mutant hAPP expression in the EC-Tau/hAPP mouse thus 353 provides a strong in vivo platform to model the impact of Aβ-associated hyperactivity on tau 354 pathology. At 16 months, somatodendritic MC1+ immunostaining was increased in the EC and 355 DG ( Figure 1C -E). By 23-months, the distribution and severity of MC1+ immunostaining 356 resembled that of much older (30+ month) EC-Tau mice ( Figure 1F ) (39, 55), suggesting that 357 hAPP/Aβ plays a significant role in promoting the intercellular transfer of pathological tau in vivo.
358
Our data supports previously published findings in similar mouse models, where robust 359 hAPP/Aβ accumulation was associated with accelerated tauopathy along the EC-HIPP network 360
(36-38). 361
We hypothesized that increased Aβ production or accumulation may trigger an 362
intermediate, non-pathogenic cascade of events that impact tau. Indeed, substantial evidence 363
exists to support the hypothesis that increased Aβ leads to neuronal hyperactivity and large-364 scale network dysfunction in the brain (24). This hypothesis may partially explain the 365 accelerated progression of pathological tau in AD and in mouse models of AD pathology. 366
hAPP/Aβ accumulation has been linked to the appearance of epileptiform-like network activity in 367 the brain at a relatively young age (21, 22, 56) . This aberrant network activity is associated with 368 changes in inhibitory neuron profiles and remodeling of the DG. More recently, hyperactive 369
neurons have been shown to disproportionately cluster around Aβ plaques in cortex (20) hyperactivity was not attributed to oversampling of neuronal bursting in the hAPP-expressing 377 mice, as no significant group differences were found in the % of EC bursting activity recorded 378
(One-way ANOVA: F (3) = 2.426, p = 0.1034) (Table 1) . Plotting the average firing rates of pooled 379 EC neurons as a function of spike width revealed a distinct population of hyperactive neurons in 380
Aβ-generating mice that was distributed among putative interneurons (NS) and excitatory cells 381
(WS) ( Figure 2D -G). This increased proportion of hyperactive cells was not due to oversampling 382 of NS neurons in Aβ-generating mice (NS, n=212) versus Non Aβ-generating mice (NS, n=196) 383 (Table 1) . Additionally, Aβ-associated EC hyperactivity and theta impairment was also present 384
after applying a minimum speed filter to the datasets, which removed neuronal activity during 385 bouts of immobility (Supplemental Figure 1) . These data support previous findings describing 386
Aβ-associated interneuron dysfunction and network hyperactivity (21, 22, 57) , and extend them 387
to putative inhibitory and excitatory neurons in EC. hAPP/Aβ-associated disruptions in theta 388 oscillatory activity are also in line with previous reports (43, 45) . Finally, we did not detect 389 hAPP/Aβ-mediated effects on behavioral activity during open field recording sessions ( Figure 4 ). 390
This is in contrast to several reports describing locomotor hyperactivity in the hAPP/J20 mouse 391 line (22, 48, 49) . We predict that this may have been due to increased motivational drive to 392 actively explore the arena in our mice, as sucrose pellets were administered during recording 393 sessions to encourage foraging behavior and arena coverage. Repeated handling and 394
acclimation to the recording paradigm may have also reduced innate anxiety-like behavior in our 395 mice, leading to similar behavioral activity patterns. Importantly, we can conclude that Aβ-396 associated neuronal hyperactivity and network dysfunction are not due to gross locomotor 397 differences in our mice. 398
Several lines of evidence now support a role for increased neuronal activity in both Aβ 399 accumulation and accelerated tau pathology in vivo. Stimulation of the perforant pathway results 400
in increased Aβ concentrations in hippocampal interstitial fluid (ISF) (30), and increased Aβ 401 deposition in downstream DG (outer molecular layer) (33). Chemogenetic stimulation of cortical 402
neurons is also associated with increased deposition of mature amyloid plaques (34). Likewise, 403
stimulating neuronal activity results in increased ISF hTau concentrations (31), and chronic 404 stimulation of EC neurons enhances local tauopathy and accelerates neurodegeneration (32). 405
These data suggest that Aβ-associated hyperactivity can impact pathological tau progression 406 along a defined neural circuit while simultaneously driving increased hAPP/Aβ release. The 407
afflicted circuit could then potentially be recruited into a harmful, positive feedback loop that 408 drives aggressive pathological hAPP/Aβ and tau aggregation in the neuronal network, leading to 409 cognitive impairment and cell death. Aged mice with significant tauopathy along the EC-HIPP 410 network exhibit deficits in spatially modulated grid cell function and impaired spatial learning and 411 memory, as well as excitatory neuron loss, independent of Aβ pathology (39, 55) . 412
Surprisingly, the increased aggregation of pathological tau in EC did not appear to affect 413 measures of hyperactivity or network function in 16-month EC-Tau mice. Single-unit average 414 firing rates, ISI medians and % theta power were remarkably similar in EC-Tau/hAPP and hAPP 415 mice, and in EC-Tau and non-transgenic Control mice. These findings support a previous report 416 from our lab describing normal EC single-unit function in 14-month EC-Tau mice, where 417 average firing rates and SM cell firing patterns matched that of non-transgenic controls (39). 418
These data suggest that the accumulation of tau in this model does not strongly impact EC 419 neuronal activity by 16-months in vivo. However, these data should be carefully interpreted, as 420 EC-hTau overexpression has been linked to hypometabolism in ~9-month mice (36) and has 421
recently been shown to blunt Aβ-associated hyperexcitability in vitro and in vivo (58, 59) . It is 422 possible then that detection of hTau-mediated effects on neuronal activity is partly dependent on 423 the sensitivity of the assays used to measure them and degree of pathological severity. Our 424 analysis in 16-month animals revealed blunted hyperactivity in NS neurons of EC-Tau/hAPP 425 mice ( Figure 2F ), which may represent an early, synergistic effect of Aβ on tau-mediated 426 inhibitory interneuron dysfunction that could precede subsequent impairments in excitatory 427 neurons and gross network function. We have shown that aged (30+ month) EC-Tau mice 428 exhibit significant hypoactivity in excitatory MEC grid cells (39). Thus, we predict that divergent 429 hAPP/Aβ and hTau effects on neuronal activity would be readily observed in the EC-HIPP 430 network of aged EC-Tau/hAPP mice. 431
We implemented a chemogenetic approach in our studies to combat the aggressive 432 progression of Aβ-associated EC hyperactivity on Aβ and tau pathology in vivo. hM4D i 433
DREADDs were targeted to EC principal neurons based on the finding that WS (wide-spiking) 434 cells showed hyperactivity in both hAPP mice and EC-Tau/hAPP mice ( Figure 2F -G). 435
Importantly, DREADDs-mediated neuromodulation has been shown to reduce local Aβ 436 deposition in cortex (hM4D i ) (34) and facilitate the transfer of hTau into distal post-synaptic cell 437 populations (hM3D q ) (13). Using a within-subjects design, we probed for hAPP/Aβ and 438 pathological tau immunoreactivity in both the ipsilateral, downstream hippocampus and in the 439 contralateral hippocampus. After 6-weeks of hM4D i EC DREADDs activation, we found a 440 marked reduction in 6E10+ immunoreactivity within ipsilateral hippocampus of EC-Tau/hAPP 441 and hAPP mice, supporting previous reports linking stimulated neuronal activity to Aβ release 442
and Aβ pathology ( Figure 5E -H) (30, 33, 34, 60, 61) . Chronic hM4D i EC DREADDs activation in 443
hTau-expressing mice also led to selective reductions in pathological tau immunoreactivity 444 within ipsilateral, downstream hippocampal subfields, as well as local regions where hM4D i 445
DREADDs were expressed (Figures 6-7, Supplemental Figure 5 ). Extensive somatodendritic 446 tau aggregates were readily observed within the hippocampus in a subset of mice 447
(characterized as exhibiting 'Advanced' tau pathology). To visualize trends in hemispheric tau 448 differences according to hippocampal subfield or tau marker, we pooled right versus left 449
hemisphere ratio values and compared group means to a hypothetical mean of 1.0, which would 450
indicate equal distribution of pathological tau in left and right hemisphere ROIs (Figure 8 ). We 451
consistently observed reduced tau pathology in ipsilateral rDG granule cells and rCA1 pyramidal 452
neurons, while no group trends were found in rSub ( Figure 8B ). These data are the first to 453 demonstrate that attenuated neuronal activity can reduce pathological tau in vivo, and support 454 previous reports showing that stimulated neuronal activity can increase tau release and 455 tauopathy in AD mouse models (12, 13, 31, 32) . 456
Recent concerns have been raised in the literature regarding the utility of CNO as an 457
inert DREADDs ligand that easily permeates the blood-brain barrier (BBB) (62-64): for review, 458
see (65). In our studies, we confirmed chronic EC DREADDs activation in vivo using recording 459 metrics derived from single, high-dose CNO injection studies. Acute hM4D i DREADDs activation 460 resulted in decreased EC neuronal activity beginning at ~20 min, with a maximal response at 461
~30 min that lasted for at least 4 hr (Supplemental Figure 2A-B) . This data is supported by 462 previous in vivo research showing strong hM4D i activation in EC 30 min post-CNO, with activity 463 levels recovering towards baseline by 12 hr (66). Acute hM4D i DREADDs activation also led to 464 a robust decrease in % theta power in EC lasting over an hour (Supplemental Figure 2D -E). 465
Therefore, we tracked chronic EC DREADDs activation in vivo by analyzing total spike counts 466
and % theta power ( Figure 5A-B ), rather than measuring levels of CNO or converted clozapine 467
in peripheral blood/plasma. Consistent with our single CNO injection findings, total spike counts 468
and % theta power were reduced over chronic CNO treatment, supporting the utility of long-term 469
CNO delivery in indwelling osmotic minipumps to activate DREADDs in vivo (see also (67)). 470
Expression of hM4D i DREADDs was restricted to the right hemisphere of our mice and 471 did not crossover into the contralateral, left hemisphere ( Figure 5C -D and Supplemental Figure  472 4). Thus, we were able to discriminate the effects of chronic EC DREADDs activation on 473 pathology in ipsilateral, downstream HIPP (right hemisphere) and directly compare it to 474 pathology in the contralateral, control left HIPP. We predict that any off-target effects of chronic, 475
converted CNO-to-clozapine on hAPP/Aβ and tau pathology would have impacted both left and 476 right hemispheres in our experimental mice, as continuous 6-week delivery of 1mg -1 /kg -1 /day -1 477
CNO was performed using minipumps. 6E10+ immunostaining revealed strong decreases in 478 hAPP/Aβ in the ipsilateral rHIPP ( Figure 5E -G), downstream of the DREADDs activated rEC. 479
We did not detect hemisphere differences in 6E10+ immunoreactivity in age-matched hAPP 480 mice or EC-Tau/hAPP mice sampled from our colony (no DREADDs manipulation), or in hM4D i 481 EC DREADDs expressing EC-Tau/hAPP mice administered a lower CNO dose (0.5mg -1 /kg -482 1 /day -1 ) ( Figure 5H and Supplemental Figure 4H ). Furthermore, regional decreases in 483 abnormally conformed tau (MC1+), phosphotau accumulation (AT8+) and total human tau 484 (CP27+) were detected in ipsilateral, rHIPP subfields after chronic hM4D i EC DREADDs 485
activation. The degree to which pathological tau and Aβ accumulation were reduced in 486
downstream HIPP, along with our electrophysiology data showing reduced neuronal activity, is 487 consistent with the hypothesis that ~50-75% maximal DREADDs activation could be achieved 488
with 1mg -1 /kg -1 /day -1 CNO (68). 489
Attenuating neuronal hyperactivity and network dysfunction may prove to be a powerful 490 tool in combating impaired cognition in human AD, especially when paired with therapies aimed 491 at alleviating the aggregation and deposition of Aβ and tau. On its own, Aβ-targeted 492 immunotherapy has proven unsuccessful at relieving AD cognitive symptoms, which may be 493 due to ineffective amelioration or the exacerbation of neuronal hyperactivity (29, 69). Indeed, 494
reducing AD pathology-associated neuronal dysfunction with the antiepileptic drug leviteracetam 495 has shown promise in preclinical mouse models of hAPP overexpression (22, 70) , and is being 496 tested for efficacy in AD clinical trials. Our data shows that alleviating Aβ-associated EC 497
hyperactivity reduces downstream accumulation of both Aβ and tau pathology in the 498
hippocampus. An important step forward will be to replicate these findings in non-499
overexpressing hAPP mice (APP NL-F/NL-F ), which show early signs of neuronal hyperexcitability 500 in vitro and impaired gamma oscillations in vivo (71-73). In addition, future studies will be 501 required to determine if relief from pathological Aβ and tau using approaches such as 502 chemogenetics will improve cognitive behavior. Interestingly, reducing murine tau levels has 503 been shown to alleviate locomotor hyperactivity in young hAPP/J20 mice and can blunt 504
pharmacologically induced aberrant over-excitation (49, 74) . This would indicate that several 505 potential mechanisms exist in the brain to contribute to impaired neuronal activity in AD, and 506 provide ample avenues for investigation into the etiology of AD progression. 507
Author Contributions 508
These experiments were designed by G. Additionally, two mice from each genotype were sampled from our colony at 10-months, 16-533 months, and 23-months of age for initial pathology studies (n=18) in Figure 1 . All mice were 534 housed in a temperature and humidity controlled vivarium at Columbia University Medical 535
Center and maintained on a standard 12 hr light/dark cycle with food and water provided ad 536 libitum. All animal experiments were performed during the light phase in accordance with 537 national guidelines (National Institutes of Health) and approved by the Institutional Animal Care 538
and Use Committee of Columbia University. 539 540
Microdrive construction 541
Microdrives were constructed as described previously (39, 77) . Briefly, custom-made reusable 542
16-channel or 32-channel microdrives (Axona, UK) were outfitted with four to eight tetrodes 543 consisting of twisted, 25 mm thick platinum-iridium wires (California Wires, USA) funneled 544 through a 23 ga stainless steel inner cannula. A 19 ga protective, stainless steel outer cannula 545
was slipped over the inner cannula and secured to the microdrive body via modeling clay. 546
Individual electrodes were wrapped tightly around the exposed wires of the microdrive and 547 coated with a layer of Pelco conductive silver paint (Ted Pella, Inc., USA) prior to sealing of the 548 microdrive body with liquid electrical tape (Gardner Bender, USA). Several hours prior to 549 surgery, the tetrodes were cut to an appropriate length and electroplated with a platinum/gold 550 solution until the impedances dropped within a range of 150-200 ohms. 551
552

DREADDs virus microinjection and tetrode implantation 553
A total of 30 mice were implanted and recorded for in vivo electrophysiology studies (Control, 554 n=7; EC-Tau, n=6; hAPP, n=9; EC-Tau/hAPP, n=8). On the day of electrode implantation, mice 555
were anesthetized with isoflurane (3-4% for induction; 0.5-3% for maintenance) using a multi-556
channel VetFlo Traditional Anesthesia vaporizer (Kent Scientific) and fixed within a stereotaxic 557 frame (Kopf Instruments). As described previously (39), an incision was made to expose the 558 skull and 3 jeweler's screws were inserted into the skull to support the microdrive implant. A 2 559 mm hole was made on each side of the skull at position 3.0-3.1 mm lateral to lambda and ~ 0.2 560 mm in front of the transverse sinus. Viral delivery of the G i -coupled hM4D i DREADD (AAV5-561
CamKII α -hM4D i -mCherry, 4.1x10 12 ) (Cat No. 50477-AAV5; Addgene, USA) was administered 562 into the right EC via a 33 ga NeuroSyringe (Hamilton, USA) tilted at an angle of 6-7 o in the 563 sagittal plane. A control virus (AAV5-CamKII α -eGFP, 4.1x10 12 ) (Cat No. 50469-AAV5; Addgene, 564 USA) was administered into the contralateral left EC using identical parameters. At this point, an 565 additional screw connected with wire was inserted into the skull, serving as a ground/reference 566 for local field potential (LFP) recordings. The prepared 16-channel microdrive was then tilted at 567 6-7 o on a stereotaxic arm and the tetrodes lowered to 1.0 mm from the surface of the brain 568 (below dura) into the DREADDs-delivered right hemisphere. The microdrive ground wire was 569 then soldered to the skull screw wire and the microdrive was secured with dental cement. Mice 570
were then allowed to recover in a cleaned cage atop a warm heating pad until awake (~45 min) 571
before being transported to the housing facility. Mice received Carprofen (5mg/kg) prior to 572 surgery and post-operatively to reduce pain, in additional to a sterile saline injection (s.c.) to aid 573 in hydration. Recording experiments began approximately one week from the time of surgery. 574
An additional cohort of 16-month hAPP (n=3) mice were microinjected with virus and 575
implanted with osmotic minipumps for long-term DREADDs activation, but did not receive 576 microdrive implants for electrophysiological recordings. 577
578
In vivo recording: single-unit and local field potential analyses 579
All mice outfitted with microdrives underwent four to six recording sessions in an arena (70 cm x 580 70 cm), with one recording session performed per day. Tetrodes for each mouse were moved 581 down 100 µm from their previous position 24 hr prior to the next recording session, allowing 582 stable electrode positioning and a robust sampling of EC neuronal activity for each mouse. 583
Additionally, the arena and visual cue were rotated between sessions. 584
Neuronal signals from our mice were recorded using the Axona DacqUSB system, and 585 described previously (39). Briefly, recording signals were amplified 10,000 to 30,000 times and 586 bandpass filtered between 0.8 and 6.7 kHz. The LFP was recorded from four channels of each 587 microdrive, amplified 8,000 to 12,000 times, lowpass filtered at 125 Hz and sampled at 250 Hz. 588
60 Hz noise was eliminated using a Notch filter. Spike sorting was performed offline using TINT 589
cluster-cutting software and Klustakwik automated clustering tool. The resulting clusters were 590
further refined manually and were validated using autocorrelation and cross-correlation 591 functions as additional separation tools. Only cells that produced a minimum of 100 spikes with 592 less than 1% refractory period violations (refractory periods < 1ms) were used for subsequent 593 analysis (41). Single-units with no undershoot in their waveform were discarded (defined as 594
Area Under the Peak < 1.0 µV 2 ). Putative excitatory neurons (WS, wide-spiking) were 595 distinguished from putative interneurons (NS, narrow-spiking) by first examining the frequency 596 distribution histogram of pooled EC single-unit spike widths, and then bisecting the waveform 597 spike widths according to the following calculation: Osmotic minipump preparation and surgical implantation 608
Following EC recording sessions, a subset of EC-Tau/hAPP (n=4) mice and EC-Tau (n=5) mice 609 underwent a second surgical procedure to chronically activate hM4D i EC DREADDs. In 610 addition, a subset of hAPP (n=3) mice that did not receive microdrive implants was subject to 611 chronic hM4D i EC DREADDs activation. Clozapine-n-oxide (CNO; Sigma Aldrich, USA) was 612 dissolved in sterile saline with 0.05% 613 24 hr prior to surgery, osmotic minipumps (Model 2006) (Alzet, USA) were primed with 614 clozapine-n-oxide (CNO) at a concentration range of 7-10µg/µL in a sterile fume hood (Alzet 615 drug concentration calculator: flow rate, 0.15µL/hr; target dose, 1mg -1 /kg -1 /day -1 ). CNO-filled 616 pumps were stored in warm (37 o C) sterile saline in a conical tube until surgery. 617
Mice were once again anesthetized with isoflurane as previously described and the fur 618 clipped at the abdomen. A single injection of marcaine (2mg/kg, 0.05mL) was delivered 619
intradermally into the site of incision ~ 5 min prior to surgery, then a midline incision was made 620
in the abdominal wall and a sterile, CNO-filled minipump was maneuvered into the 621 intraperitoneal (i.p.) cavity. The incision was then closed using an absorbable suture (Henry 622
Schein, USA) for the abdominal layer, followed by closure of the skin with a nylon synthetic non-623 absorbable suture (Henry Schein, USA). A topical antibiotic was then administered at the 624 surgical site and the mice were allowed to recover in a cleaned cage atop a warm heating pad 625 until awake (~15 min). Mice implanted with minipumps were administered Carprofen (5mg/kg) 626
prior to surgery and post-operatively to help reduce pain. Non-absorbable sutures were 627 removed ~10 days after surgery. 628
629
DAB immunohistochemistry and immunofluorescence imaging 630
At 6 weeks, all mice were deeply anesthetized with a cocktail of ketamine/xylazine before being 631
transcardially perfused with ice-cold 100mM phosphate-buffered saline (PBS) pH 7.4., followed 632 by 10% formalin (Fisher Scientific, USA). The last recording position for each microdrive-633
implanted mouse was recorded, and then the microdrive removed. Brains were then harvested 634 and left in 10% formalin overnight, then incubated in 30% sucrose until the brains sank to the 635 bottom of the conical tube (all at 4 o C). Horizontal brain sections were sliced (30µm) using a 636
Leica CM3050 S cryostat and stored in cryoprotectant at -20 o C until immunostaining 637
procedures. For both immunoperoxidase staining and immunofluorescence imaging, EC-638
Tau/hAPP brain sections were processed in parallel with sections from EC-Tau and hAPP mice, 639
and non-transgenic Control mice where appropriate. Finally, all tissue sections included for 640 semiquantitative analysis of hAPP/Aβ (Figure 4 ) and tau (Figure 7) were verified to be within the 641 range of DREADDs mCherry expression by first checking for native fluorescence signal in free-642
floating sections on an inverted Olympus epifluorescence microscope. 643
Immunoperoxidase staining was performed using a Mouse-on-Mouse kit (Vector 644
Laboratories, USA) and modified from previous methodology (11, 39, 55) . Briefly, cryoprotectant 645 was washed from the free-floating tissue sections with PBS before quenching endogenous 646 peroxidases with 3% H 2 O 2 . Sections were then blocked with mouse IgG blocking reagent for 1.5 647 hr at room temperature, followed by overnight incubation at 4 o C with either anti-beta amyloid 648 6E10 (mouse, 1:1,000 dilution of 1mg/mL stock) (Biolegend, USA), anti-tau MC1 (mouse, 1:500; 649 courtesy of Peter Davies, Albert Einstein College of Medicine), biotinylated anti-phospho 650 tau Ser202/Thr205 AT8 (mouse, 1:500) (Thermo Scientific, USA) or anti-human tau CP27 (mouse, 651 1:500; courtesy of Peter Davies, Albert Einstein College of Medicine). Tissue sections were then 652 rinsed in PBS and incubated for ~20 min at room temperature in a working solution of 653 biotinylated anti-mouse IgG reagent (excluding the biotinylated AT8-labeled sections). After 654 several PBS rinses, sections were then incubated in an avidin-biotin conjugate for 10 min before 655
being developed in H 2 O containing 3'3'-diaminobenzidine (DAB) hydrochloride and urea 656 hydrogen peroxide (Sigma Aldrich, USA). After staining was completed, tissue sections were 657 mounted onto glass Superfrost Plus slides (Fisher Scientific, USA), allowed to air dry 658 completely, and then dehydrated in ethanol and cleared with xylenes before being coverslipped. 659
Horizontal tissue sections used to visualize native DREADDs mCherry and eGFP 660 expression in the brain were first rinsed in PBS containing 0.3%Triton X-100 (Sigma Aldrich, 661
USA) (PBST) and then incubated in a working solution of Hoechst 33342 dye (5µg/mL) (Thermo 662
Scientific, USA) to stain cell nuclei for 10 min at room temperature. Subsequent washes in 663
PBST were followed by mounting the tissue onto Superfrost Plus slides and coverslipping using 664
SlowFade gold anti-fade reagent (Life Technologies, USA). All slides were stored in the dark at 665 4 o C until imaging. 666
667
DAB IHC image analysis 668
Immunoperoxidase-stained tissue sections were analyzed under bright field microscopy using 669
an Olympus BX53 upright microscope. Digital images were acquired using an Olympus DP72 670 12.5 Megapixel cooled digital color camera connected to a Dell computer running the Olympus 671 cellSens software platform. Image files were then coded and analyzed by an investigator 672 blinded to genotype and saved to a Dell Optiplex 7020 (79). 673
Semiquantitative analysis of MC1+ cell counts in EC and DG was performed in 674 horizontal brain sections from 16-month EC-Tau/hAPP mice (n=4) and EC-Tau mice (n=5) 675
( Figure 1E ). MC1+ cells within defined ROIs (EC and DG granule cell layers) were counted 676 using the multi-point tool and saved via the ROI Manager. The estimated total number of MC1+ 677 cells/mm 2 was then calculated per left and right hemisphere ROI in each section and averaged 678 across three sections per mouse to generate a representative value. Finally, MC1+ cells/mm 2 679 values for each ROI were pooled and compared across genotype. Only cells with clear 680 somatodendritic accumulation of MC1+ immunoreactivity were included in our analysis. 681
For DAB IHC threshold analysis, minimum threshold values for 8-bit, grayscale images 682 of immunoperoxidase-stained sections were adjusted interactively under blinded conditions in 683
Fiji using an over/under display mode (red represents pixels above threshold) (Supplemental 684 Figure 3A & 3F) . A region of interest (ROI) was then defined within each image and saved via 685
the ROI Manager. The total immunoreactivity for each antibody marker above threshold was 686 saved as a percentage of total ROI area (mm 2 ) and used to compare pathological accumulation 687 of hAPP/Aβ and tau in the right versus left hemispheres. The same minimum threshold value 688
was applied for each pair of images (right vs left ROIs) used in our analysis. For all DAB IHC 689 experiments, three immunostained tissue sections were analyzed per mouse and averaged to 690 generate a representative value reflecting hAPP/Aβ and tau pathology. 691 692
Behavioral analysis 693
Animal performance during in vivo recording sessions was assessed by tracking the position of 694 an infrared LED on the head stage (position sampling frequency, 50 Hz) by means of an 695 overhead video camera. The position data were first centered around the point (0, 0), and then 696 speed filtered where noted, with only speeds of 5 cm/sec or more included in the analysis. 697
Tracking artifacts were removed by deleting samples greater than 100 cm/sec and missing 698 positions were interpolated with total durations less than 1 sec, and then smoothing the path 699 using a moving average filter with a window size of 300 ms (15 samples on each side). The total 700 distance traveled in the arena (m), % of arena coverage, and average speed (cm/sec) during 701 exploration served as dependent measures of interest. For % of arena coverage, the processed 702 position data was plotted and converted to black and white. Using the 'bwarea' function in 703
MATLAB, we calculated the total area traveled by the mouse using the binary image, and then 704 divided this area by the total area of the arena. For each dependent measure, an average value 705 per mouse was generated by collapsing three individual recording sessions that occurred over 706 three days. Values for the entire session were then pooled per genotype and compared, or split 707 into the following time bins and compared: the first 5 min, 10 min and 15 min of the total 708 recording session (30 min). 709 710
Tools for semi-automated data analysis 711
BatchTINTV3: BatchTINTV3 is a graphical user interface (GUI) written in Python, and created 712
as an end-user friendly batch processing solution to complement Axona's command line 713
interface. BatchTINTV3 sorts the spike data of each session in a chosen directory using 714
KlustaKwik. The BatchTINTV3 code is freely available and hosted in the following GitHub 715 repository: https://github.com/hussainilab/BatchTINTV3. 716
BatchPowerSpectrum: The percent power values were calculated in MATLAB. A 717
Welch's power spectrum density (PSD) estimate of the LFP was calculated via the 'pwelch' 718 function. Using the PSD, the average powers in each of the desired frequency bands were 719 calculated with the 'bandpower' function. The average power of each band was then divided by 720 the total power of the signal to produce the percentage power in each of the bands. In situations 721
where the data was speed filtered (5-30 cm/sec), the speed of the animal was calculated and 722 then interpolated so there was a speed value for each LFP value. Then the LFP values were 723 chunked to contain consecutive data points where the mouse's movements satisfied the 724 minimum and maximum speed requirements. Chunks containing less than 1 second of data 725
were discarded. The aforementioned power calculations were then performed on each of the 726 LFP chunks, and an average of these chunks would yield the final percentage power values for 727 each of the frequency ranges. The BatchPowerSpectrum code is freely available and hosted in 728 the following GitHub repository: https://github.com/hussainilab/BatchPowerSpectrum. 729 hfoGUI for time-frequency analysis: A time-frequency representation (TFR) of the LFP 730 was visualized using a GUI written in Python called 'hfoGUI.py'. The GUI allows for complete 731 control of signal filtering and is equipped with various filter types (butterworth, chebyshev type 1, 732 chebyshev type 2, etc.), along with the ability to specify filter order, cutoffs, etc. We used 3rd 733 order butterworth filters in order to maintain consistency with the filter types and order 734
implemented by the Axona data acquisition software/hardware. Specific time windows of the 735 LFP data were selected and subjected to a Stockwell-Transform (s-transform) to visually 736 represent EC-Tau/hAPP and Control genotypes ( Figure 3A-B) . The hfoGUI code is freely 737 available and hosted in the following GitHub repository: https://github.com/hussainilab/hfoGUI. 738 739
Statistical Analysis 740
Statistical analyses were performed in GraphPad Prism 7 and Matlab. All datasets were tested 741
for normality using the Shapiro-Wilk test. Datasets where values were not well modeled by a 742 normal distribution were subjected to non-parametric statistical analyses. Unpaired t-tests with 743
Welsh's correction were used to perform semiquantitative comparisons of tau pathology in 744 in Figure 4 . A repeated measures ANOVA was used to calculate the difference in % theta power 749 over time in Figure 5 (compared to baseline) . Paired t-tests were used to compare 6E10+ 750 immunostaining in the DREADDs activated right hemisphere versus Control left hemisphere in 751 Figure 5 . One-sample t-tests were used to compare averaged right versus left hemisphere 752 ratios for tau markers to a theoretical mean (1.0) in Figure 8 . Abeta plaques in a mouse model of Abeta deposition. J Neuroinflammation. 2014;11:111. 950
Figure Legends
Figure 1. Aβ-associated acceleration of tau pathology along the EC-HIPP network
Horizontal brain sections from EC-Tau/hAPP mice and age-matched EC-Tau littermates were processed for immunohistochemical detection of hAPP/Aβ (6E10) and abnormal, misfolded tau (MC1). Representative, adjacent brain sections from two mice sampled are shown for both 6E10 and MC1. A-B . 16-month EC-Tau/hAPP mice exhibited robust Aβ accumulation and plaque deposition throughout the EC and HIPP. Diffuse Aβ accumulation comprised the majority of the pathology in these regions, with occasional small, compact plaques and large, dense-core Aβ plaques present (arrows). EC-Tau mice did not exhibit 6E10+ immunoreactivity. Scale bars, 500µm. C-D. MC1+ immunostaining revealed a clear acceleration of tau pathology in the EC of EC-Tau/hAPP mice, characterized by an increased number of cells with abnormally conformed tau localized to the somatodendritic compartment. Scale bars, 250µm. E. A semiquantitative analysis of MC1+ cell counts was performed in the EC and DG. EC-Tau/hAPP brain sections exhibited over three-fold and over ten-fold greater MC1+ cell counts in EC and DG than in EC-Tau sections, respectively. Unpaired t-tests with Welch's correction: EC, p < 0.01; DG, p < 0.05. F. MC1+ immunostaining in EC-Tau/hAPP mice sampled at 10-, 16-, and 23-months of age confirmed the onset of pathological tau spread from the EC into the HIPP at 16-months. Graphs represent mean ± SEM for the averaged ROI values from three independently processed brain sections per mouse. * p < 0.05; ** p < 0.01.
Figure 2. Aβ-associated hyperactivity in EC single-units in vivo
In vivo multi-electrode recordings were performed in the EC of 16-month EC-Tau/hAPP mice (n=4) and their age-matched littermates: EC-Tau (n=4), hAPP (n=5), and non-transgenic control mice (n=7). A. MC1 immunostained horizontal brain section from a 16-month EC-Tau/hAPP mouse. Representative image depicts tetrode tract mark terminating in EC layer II. Scale bar, 500µm. B. Cumulative frequency distributions of the spontaneous, average firing rates of all single-units collected in EC-Tau/hAPP mice and age-matched littermates. Pooled EC-Tau/hAPP neurons and hAPP neurons each exhibit shifts in their distributions towards higher firing rates versus Control. Two-sample Kolmogorov-Smirnov test: (EC-Tau/hAPP vs Control: p < 0.001; hAPP vs Control: p < 0.001). Insert, histograms of mean average firing rates are shown for each genotype. The single-unit average firing rates of EC-Tau/hAPP mice and hAPP mice were nearly two-fold higher than Control. Kruskal-Wallis test: p < 0.001. C. Cumulative frequency distributions of the median inter-spike intervals (ISI) for pooled EC single-units. Two-sample Kolmogorov-Smirnov test: (EC-Tau/hAPP vs Control: p < 0.001; hAPP vs Control: p < 0.001). Insert, box-and-whisker plots depicting median and mean ISI values along with 10-90 percentile limits per genotype. EC single-unit ISI values were significantly decreased in EC-Tau/hAPP mice and hAPP mice compared to Control. Kruskal-Wallis test: p < 0.001. D. EC single-unit average firing rates were plotted as a function of waveform spike-width and color-coded based on whether they belonged to Aβ-generating mice (purple) or Non Aβ-generating mice (gray). A distinct population of hyperactive EC neurons were present in Aβ-generating mice, and were distributed along the x-axis (shorter to longer spike-widths). E. Frequency histogram of neuronal spike widths for all single-units; note the bimodal distribution. A cutoff of 300µm spike-width was used to delineate putative interneurons (NS, narrow-spiking cells; yellow) from putative excitatory neurons (WS, wide-spiking cells; blue) (broken arrow). F. hAPP NS cells exhibit increased average firing rates compared to Controls. Kruskal-Wallis test: p < 0.05. G. EC-Tau/hAPP WS cells and hAPP WS cells each exhibit increased average firing rates versus Control WS cells. Kruskal-Wallis test: p < 0.001. Bar graphs represent mean ± SEM. * p < 0.05; *** p < 0.001. were analyzed and compared across genotype: the total distance traveled (m), the % arena coverage and average speed (cm/sec). No significant group differences were detected on any measure. One-way ANOVA tests: Total distance (m), F (3,25) = 1.540, p > 0.05; % of arena coverage, F (3,25) = 1.281, p > 0.05; average speed (cm/sec), F (3,25) = 1.632, p > 0.05. E-G. No significant group differences were detected on any dependent measure when analyzing position data in the first 5, 10 or 15 min of the recording sessions (One-way ANOVA tests; p > 0.05). Bar graphs represent mean ± SEM. Individual values (transparent overlays) are representative means from three averaged recording sessions per mouse.
Figure 5. Chronic hM4D i EC DREADDs activation reduces Aβ pathology in downstream hippocampus
16-month EC-Tau/hAPP (n=4) mice and age-matched littermates (EC-Tau, n=5; hAPP, n=3) expressing hM4D i EC DREADDS were subjected to 6-weeks of DREADDS activation via osmotic minipumps (CNO, 1mg -1 /kg -1 /day -1 ). A-B. Neuronal activity was examined in vivo for EC-Tau/hAPP and EC-Tau mice (n=9) and analyzed at time-points corresponding to the last three weeks of drug treatment (T4, T5 and T6). Chronic hM4D i EC DREADDs activation reduced total spike counts from separated cells (~25% reduction), and reduced % theta power versus baseline recordings. Repeated measures ANOVA: F (3,7) = 5.157, p < 0.01. Dunnett's multiple comparison test. C-D. An overlay of individual mCherry (hM4D i DREADDs) and eGFP (control virus) expression patterns for EC-Tau/hAPP mice and transgenic littermates is shown (n = 12 mice). hM4D i DREADDs expression in the right hemisphere was localized to cell bodies and neuropil throughout the EC, pre-and para-subiculum, and subiculum, with occasional mCherry signal present at terminal ends of axons in the outer 2/3 molecular layer of DG. Representative IF images from a 16-month EC-Tau/hAPP mouse are shown. Scale bars, 250 µm. E-F. 6E10+-immunostained brain sections are shown for two EC-Tau/hAPP and hAPP mice. hAPP/Aβ accumulation is reduced in ipsilateral HIPP compared to contralateral HIPP. Scale bars, 500µm. G. Semiquantitative analysis of HIPP 6E10+ immunoreactivity was performed and compared across hemispheres (EC-Tau/hAPP, n=4; hAPP, n=3). Image thresholding analysis revealed a significant reduction in 6E10+ immunoreactivity in the ipsilateral HIPP, expressed as a % of the HIPP region (ipsi HIPP: 8.85 ± 1.03 % vs contra HIPP: 14.92 ± 1.95 %). Paired t-test: t (6) = 4.552, p < 0.01. H. HIPP 6E10+ immunoreactivity did not differ between right and left hemispheres in 16-18 month EC-Tau/hAPP (n=2) mice and hAPP (n=4) mice that received no DREADDs-CNO manipulation, or in EC-Tau/hAPP (n=4) mice that were administered a low dose of 0.5mg -1 /kg -1 /day -1 CNO for 6-weeks. Paired t-test: t (8) = 1.648, p > 0.05. All graphical representations appear as mean ± SEM. Colored bar overlays in Figure  5G -H depict the mean left vs right HIPP 6E10 % values from three immunostained brain sections per mouse. ** p < 0.01.
Figure 6. Chronic hM4D i EC DREADDS activation reduces MC1+ staining along the EC-HIPP network
DAB-IHC was performed on horizontal brain sections from 16-month EC-Tau/hAPP (n=4) mice and age-matched, littermate EC-Tau (n=5) mice to evaluate the impact of chronic hM4D i EC DREADDs activation on abnormally conformed tau (MC1). MC1+ immunoreactivity patterns along the EC-HIPP network revealed a distinct separation between mice exhibiting early tau pathology, localized primarily within the EC but not yet in the HIPP, and mice exhibiting significant tau pathology in both the EC and HIPP. We refer to these mice as exhibiting Early Tau 
Figure 8. Chronic hM4D i EC DREADDS activation selectively reduces tau pathology in downstream hippocampus
Semi-quantitative analysis of tau pathology expression in HIPP was performed on MC1+, AT8+ and CP27+ immunostained tissue sections of mice exhibiting advanced tau pathology. Withinsubject comparisons of tau immunoreactivity (right versus left hemisphere) were calculated per hippocampal region of interest (CA1, DG and Sub) and then plotted as a ratio to reveal any laterality in pathological tau accumulation. Chronic activation of hM4D i EC DREADDs in the right hemisphere was associated with reduced MC1+, AT8+ and CP27+ immunostaining in DG granule cells. DREADDs activation was also associated with reduced AT8+ and CP27+ immunostaining in CA1 pyramidal cells. Box plots depict the mean ± SEM of right versus left hemisphere % Area ratios for experimental mice exhibiting advanced tau pathology (Total, n=4 mice: EC-Tau, n=2; EC-Tau/hAPP, n=2). Black boxes, MC1; Gray, AT8; White, CP27. Transparent, colored overlays depict individual ratio values for each mouse. Hashed line (1.0 ratio) represents equal right versus left hemisphere tau immunoreactivity. Table 1 
Supplemental Figure Legends
. Single-unit totals and average firing rates per mouse
In vivo electrophysiological recording parameters are shown for individual mice included in the study. The total number of cells and their average firing rates are listed, as well the average firing rates and total numbers of narrow-spiking (NS) and wide-spiking (WS) cells per mouse. Finally, the averaged bursting activity % per mouse is listed. vivo. A-B . Long-term recordings were first performed in naïve 12-13 month EC-Tau mice to determine the onset and duration of altered single-unit activity due to EC DREADDs activation (hM3D q EC, n=1 mouse; hM4D i EC, n=1 mouse). Left, Total spike counts (normalized to baseline measures) are shown for each mouse following CNO and Saline administration (60 min post-treatment). EC DREADDs activation occurs ~20 min post-CNO compared to Saline and lasts at least 4 hr (right). Square (green), hM3D q EC DREADDs; Diamond (purple), hM4D i EC DREADDs; Circle (white), Saline. C. Sagittal sections from an EC-Tau mouse expressing hM3D q EC DREADDs is shown. DREADDs-mCherry expression is present along the dorsoventral axis of the EC. Tetrode tract is shown. Scale bars, 500µm. D. The effects of acute hM4D i EC DREADDs activation on LFP measures in EC are shown in a 12month hAPP/J20 mouse. LFP traces are shown for both CNO and Saline conditions. Notable differences in EC theta modulation were present after 10mg/kg CNO treatment. E. To determine the long-term effects of CNO treatment on LFP measures, the magnitude difference in % theta, % low gamma and % high gamma power versus Saline were calculated. % theta power and % high gamma power in EC were robustly affected by CNO treatment for over an hour. TD Ratio is the normalized Treatment Difference ratio showing magnitude difference of CNO treatment vs Saline.
Supplemental Figure 1. Speed filtered EC single-unit firing rates and network activity
Supplemental Figure 3. Right vs left hemisphere ROI measures for DAB IHC analysis
The ipsilateral HIPP regions of interest (ROI) area (mm 2 ) downstream from the hM4D i DREADDs-expressing EC were compared to contralateral HIPP ROIs. Positive immunoreactivity for each marker was also analyzed within each defined ROI and compared across hemispheres as described in Methods. A. Top, 8-bit gray scale images of 6E10+ immunoreactivity in a horizontal brain section from a 16-month EC-Tau/hAPP mouse. A minimum threshold value was first applied to each image (186), and then the ROIs (lHIPP and rHIPP) were defined (magenta). Finally, the % area of 6E10+ immunoreactivity above threshold was used to quantify hAPP/Aβ accumulation in the right and left HIPP ROIs. Scale bars, 500µm. Bottom, Higher magnification of 6E10+ immunoreactivity within ROIs. Black pixels depict 6E10+ immunoreactivity above threshold on a white background. Scale bars, 250µm. B. Right vs left hippocampal ROI values (area, mm 2 ) for each tissue section analyzed in Figure 4G -H. The coefficient of determination (R 2 , 0.6027) is shown. C. The averaged ROI area values did not differ between the right hemispheres (1.731 ± 0.039 mm 2 ) and left hemispheres (1.737 ± 0.039 mm 2 ). Paired t test: t (6) = 0.1557, p > 0.05. Three sections averaged per mouse. EC-Tau/hAPP, n=4 mice; hAPP, n=3 mice. D. The averaged ROI area values did not differ between the right hemispheres (1.910 ± 0.040 mm 2 ) and the left hemispheres (1.899 ± 0.037 mm 2 ) in control conditions. Paired t test: t (6) = 0.5382, p > 0.05. E. 8-bit gray scale images of MC1+ immunoreactivity in the left and right dentate gyrus (DG) of a 16-month EC-Tau/hAPP mouse. A minimum threshold value (180) was applied and the granule cell layers were delineated in black. Within the ROIs, the % area of MC1+ immunoreactivity above threshold was quantified. Accompanying black and white over/under images are shown to emphasis MC1+ signal in DG ROIs. Scale bars, 100µm. F-H. The right versus left ROI values (mm 2 ) for hippocampal subregions analyzed were plotted. CA1: R 2 =0.8507; DG granule cells: R 2 =0.6529; Subiculum: R 2 =0.5711. Bar graphs represent mean ± SEM. Colored bar overlays depict the mean right versus left HIPP ROI area (mm 2 ) values for each mouse.
Supplemental Figure 4. hM4D i EC DREADDs expression in experimental mice
Regional mCherry (hM4D i DREADDS) and eGFP (Control) expression patterns were verified in all mice. For each group, illustrated mCherry and eGFP expression patterns were overlaid onto a mouse stereotaxic brain atlas. A. EC-Tau mice (n=5) exhibit robust hM4D i DREADDs expression throughout the rEC, rPaS and rPrS. mCherry signal was present in the rSub of two mice, and in terminal ends of EC projection neurons (outer molecular layers of rDG and rCA2) from one mouse. No mCherry crossover was detected in the left hemisphere. Widespread eGFP expression was detected in lEC and lPaS, as well as lSub, lCA1, and outer molecular layers of lDG. No crossover of eGFP expression into the right hemisphere was detected. B. mCherry and eGFP expression patterns are shown for three individual EC-Tau mice. C. hAPP mice (n=3) exhibit hM4D i DREADDs expression throughout the rMEC, rPaS and rPrS. DREADDs were expressed in the rSub of two mice, while mCherry signal could be seen in the terminal ends of EC projection neurons from one mouse. No crossover of mCherry expression was detected in the left hemisphere. eGFP signal was confined to the left hemisphere, with robust expression in the lMEC, lPaS, lPrS and lSub. eGFP signal was also detected in the outer molecular layers of lDG and in some lDG granule cells. D. mCherry and eGFP expression patterns are shown for all three hAPP mice. E. EC-Tau/hAPP mice (n=4) exhibit hM4D i DREADDs expression throughout the rEC, rPaS and rPrS. No crossover of mCherry expression was detected in the left hemisphere. eGFP expression was less regionally constrained in this group, and appeared in portions of the lMEC , lPaS, and lSub, as well as in the outer molecular layers of lDG, and in lCA1 (stratum radiatum and pyramidale). eGFP expression crossed over into the rPaS of one mouse. F. mCherry and eGFP expression patterns are shown for three individual EC-Tau/hAPP mice. G. mCherry and eGFP expression patterns were combined for all animals (Total, n=12 mice). H. Merged hM4D i DREADDs mCherry expression patterns are shown for 16-month EC-Tau/hAPP mice (n=4) chronically treated with low dose CNO (0.5mg -1 /kg -1 /day -1 ). Scale bars, 250µm.
Supplemental Figure 5. Chronic hM4D i EC DREADDS activation reduces total human tau along the EC-HIPP network
Adjacent tissue sections from hM4D i EC DREADDs activated mice were processed for CP27+ immunostaining experiments to examine the distribution of total human tau expression along the EC-HIPP network. Horizontal brain sections from 16-month EC-Tau/hAPP (n=4) 
